Nat. Rev. Neurol. doi: /nrneurol

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi: /nrneurol

From: The evolution and pathology of frontotemporal dementia

Bipolar treatment efficacy

Figure 4 Progression-free survival, according to treatment group

Figure 3 Life expectancy at birth in all countries included

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Cerebrospinal fluid levels of neurofilament light chain

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Overview of risk factors for Parkinson disease dementia

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Patterns of brain atrophy in Alzheimer disease

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 3D magnetic resonance neurography

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 2 Use of a brain–computer interface in severe chronic stroke

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Grey matter atrophy in FTD

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Characterization of anatomical damage

Figure 2 Imaging of atherosclerotic plaque burden

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Urol. doi: /nrurol

Figure 2 Algorithm for immunosuppressive treatment

Figure 1 Principles of therapeutic ultrasound

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 2 Global cost of HF per capita in 2012

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

A 74-year old woman with progressive amnesia

Figure 1 Proportional motor recovery in the upper limb

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Volume 14, Issue 3, Pages (March 2015)

Figure 2 Frequency and overlap of alterations

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Diagnosing neuropathic pain

Genetic Investigations of Kidney Disease: Core Curriculum 2013

Volume 17, Issue 2, Pages (February 2018)

Figure 2 DTI values between the hepatitis C group and controls(A) DTI FA values, (B) DTI diffusion values. *Statistically significant at FDR-adjusted p.

Figure 1 Timing of the effects of deep brain stimulation

Figure 1 Endovascular treatment in acute ischaemic stroke

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Figure 4 Jean-Martin Charcot (1825–1893)

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Overview of the imaging biomarker roadmap

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 A case of early-onset PSD

Improving management of neonatal infections

Figure 2 Neuroimaging characteristics of TARDBP carriers

Figure 2 Characteristic MRI features of adult leukodystrophies

Dissected Meyer’s loop with the inferior occipitofrontal fasciculus and the uncinate fasciculus.A, Photograph of the lateral aspect of a dissected cerebral.

Disintegrating Brain Networks: from Syndromes to Molecular Nexopathies

Presentation transcript:

Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.75 Figure 3 Imaging abnormalities in the presymptomatic stage of genetic FTD Figure 3 | Imaging abnormalities in the presymptomatic stage of genetic FTD. a | Grey matter changes from the Genetic Frontotemporal Dementia Initiative (GENFI) study: standardized difference between all (presymptomatic and symptomatic) mutation carriers and noncarriers in cortical grey matter volumetric imaging measures, versus estimated number of years from expected symptom onset for a given difference in volume between carriers and noncarriers. Dotted lines on the x-axis show the time at which the upper 95% confidence intervals for each curve crosses zero on the y-axis (that is, the point at which a statistically significant difference exists between mutation carriers and noncarriers). b | Changes in fractional anisotropy (red) as measured by diffusion tensor imaging. Presymptomatic carriers of GRN and MAPT mutations have decreased fractional anisotropy in the uncinate fasciculus versus control individuals. c | Changes in brain perfusion (red) as measured by arterial spin labelling. Presymptomatic GRN mutation carriers have a lower cross-sectional cerebral blood flow at follow-up than in control individuals. Part a modified with permission from Elsevier © Rohrer, J. D. et al. Lancet. Neurol. 14, 253–262 (2015) under a Creative Commons CC BY 4.0 license. Part b reproduced with permission from Lippincott Williams & Wilkins © Dopper, E. G. et al. NeuroIogy 80, 814–823 (2013) http://bit.ly/2rAsnKd. Part c reproduced with permission from Elsevier © Dopper, E. G. et al. NeuroImage. Clin. 12, 460–465 (2016). Part a modified with permission from Elsevier © Rohrer, J. D. et al. Lancet. Neurol. 14, 253–262 (2015) under a Creative Commons CC BY 4.0 license. Part b reproduced with permission from Lippincott Williams & Wilkins © Dopper, E. G. et al. NeuroIogy 80, 814–823 (2013) http://bit.ly/2rAsnKd. Part c reproduced with permission from Elsevier © Dopper, E. G. et al. NeuroImage. Clin. 12, 460–465 (2016). Meeter, L. H. et al. (2017) Imaging and fluid biomarkers in frontotemporal dementia Nat. Rev. Neurol. doi:10.1038/nrneurol.2017.75